A growing consensus endorses a “pillared” approach to diabetic kidney disease (DKD) management, wherein SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) are added to RAS blockade in patients with albuminuria. The gene discussed is SLC5A2; the disease is diabetic kidney disease.